EUVIMEDEUVIMED entdecken
Open Access

Stimulation and Medication Effects on Subthalamic Nucleus Beta‐Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation

Lauren H Hammer iD, Stephanie Cernera iD, Carina R Oehrn iD, Jiaang Yao iD, Maria Shcherbakova iD, Amelia G Hahn iD, Simon Little iD, Philip A Starr iD

Movement Disorders · 2026

DOI: 10.1002/mds.70261 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Lauren H Hammer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of California, San Francisco, San Francisco, California, USA. Hauptthemen laut MEDLINE: Deep Brain Stimulation, Parkinson Disease, Subthalamic Nucleus, Beta Rhythm. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Thiemann Stiftung Parkinson Fellowship, Chinese University of Hong Kong Charitable Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Adaptive deep brain stimulation (aDBS) using subthalamic nucleus (STN) beta‐band oscillations as a biomarker for the akinetic‐rigid symptoms of Parkinson's disease has been proposed to improve the efficacy of stimulation and decrease adverse effects. However, most studies validating STN beta oscillations as a biomarker used perioperative, off medication, and OFF stimulation conditions, limiting their potential relevance to real‐world aDBS deployment.

Objective

We evaluated how stimulation and dopaminergic medication affect beta‐range STN oscillatory activity and its ability to predict the hypokinetic parkinsonian state.

Methods

In six patients with Parkinson's disease who experienced residual levodopa‐related motor fluctuations despite standard‐of‐care DBS, we studied medication cycle‐induced fluctuations of peak STN beta oscillation power during active DBS. We evaluated the magnitude of beta oscillation fluctuations, the frequency of peak beta activity, and the ability to predict the off medication state. Neural signals were collected in the clinic during a medication challenge and at home during naturalistic medication cycles.

Results

Medication‐induced beta oscillation fluctuations were smaller in the presence of therapeutic DBS compared with when the stimulator was off ( P = 0.008). Therapeutic stimulation also decreased the frequency of peak beta activity ( P < 0.001). As a result, the beta frequencies with the highest power in the OFF stimulation/ off medication state were less accurate than other beta‐range bands at predicting the patient's off medication state during active stimulation ( P = 0.02).

Conclusions

The spectral characteristics of STN beta oscillations and their performance as a biomarker in aDBS for Parkinson's disease are influenced by the stimulation and medication conditions in which it is implemented. © 2026 International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Deep Brain StimulationParkinson DiseaseSubthalamic NucleusBeta RhythmAntiparkinson AgentsHumansFemaleMaleMiddle AgedAgedLevodopa

Stichwörter der Autor:innen

Adaptive deep brain stimulationBeta oscillationsDeep brain stimulationParkinson's diseaseSubthalamic nucleus

Substanzen

Antiparkinson AgentsLevodopa

Autor:innen und Institutionen

  • Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
  • Department of Neurology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Center for Neuroengineering and Therapeutics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
  • Department of Neurological Surgery, University of California, Davis, Davis, California, USA.
  • Center for Neuroscience at the University of California, Davis, Davis, California, USA.

ORCID-Profile: Lauren H Hammer, Stephanie Cernera, Carina R Oehrn, Jiaang Yao, Maria Shcherbakova, Amelia G Hahn, Simon Little, Philip A Starr

Förderung

  • NINDS NIH HHS
  • Thiemann Stiftung Parkinson Fellowship
  • Chinese University of Hong Kong Charitable Trust
  • Parkinson's Foundation
  • National Institute of Neurological Disorders and Stroke

Zitieren

APA

Hammer, L. H., Cernera, S., Oehrn, C. R., Yao, J., Shcherbakova, M., Hahn, A. G., Little, S., & Starr, P. A. (2026). Stimulation and Medication Effects on Subthalamic Nucleus Beta‐Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation. Movement Disorders. https://doi.org/10.1002/mds.70261

Vancouver

Hammer LH, Cernera S, Oehrn CR, Yao J, Shcherbakova M, Hahn AG, et al. Stimulation and Medication Effects on Subthalamic Nucleus Beta‐Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation. Movement Disorders. 2026. doi:10.1002/mds.70261

BibTeX
@article{Hammer2026,
  author = {Hammer, Lauren H and Cernera, Stephanie and Oehrn, Carina R and Yao, Jiaang and Shcherbakova, Maria and Hahn, Amelia G and Little, Simon and Starr, Philip A},
  title = {Stimulation and Medication Effects on Subthalamic Nucleus Beta‐Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70261}
}
Kostenlos starten →